Mitochondrial inhibitors: a new horizon in breast cancer therapy
Breast cancer, due to resistance to standard therapies such as endocrine therapy, anti-HER2 therapy and chemotherapy, continues to pose a major health challenge. A growing body of research emphasizes the heterogeneity and plasticity of metabolism in breast cancer. Because differences in subtypes exh...
Saved in:
Main Authors: | Yalan Yan (Author), Sijie Li (Author), Lanqian Su (Author), Xinrui Tang (Author), Xiaoyan Chen (Author), Xiang Gu (Author), Guanhu Yang (Author), Hao Chi (Author), Shangke Huang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exploiting gender-based biomarkers and drug targets: advancing personalized therapeutic strategies in hepatocellular carcinoma
by: Lanqian Su, et al.
Published: (2024) -
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
by: Paolo Tarantino, et al.
Published: (2021) -
New vaccines on the horizon
by: Arsenović-Ranin Nevena
Published: (2019) -
Synergizing Immunotherapy and Antibody-Drug Conjugates: New Horizons in Breast Cancer Therapy
by: Antonello Pinto, et al.
Published: (2024) -
New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?
by: Ricky Hao Chen, et al.
Published: (2024)